• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Long time interval between multiple sclerosis onset and occurrence of primary Sjögren's syndrome in a woman treated with interferon-beta.

作者信息

De Santi L, Costantini M C, Annunziata P

机构信息

Department of Neurological and Behavioural Sciences, University of Siena, Siena, Italy.

出版信息

Acta Neurol Scand. 2005 Sep;112(3):194-6. doi: 10.1111/j.1600-0404.2005.00455.x.

DOI:10.1111/j.1600-0404.2005.00455.x
PMID:16097964
Abstract

Primary Sjören's syndrome with central nervous system involvement can clinically mimic multiple sclerosis (MS). However, SS and MS may coexist. We report here a case of a 48-year-old woman affected by relapsing-remitting MS, good responder to interferon (IFN)-beta 1a, developing sicca complex after 29 years from MS onset. At the age of 48, after 5 years successful treatment with i.m. IFN-beta 1a, xerophtalmia and xerostomia with dysphagia occurred. Autoantibody screening for connective tissue diseases, including anti-ENA, was negative. Schirmer's test showed reduced lacrimal gland function and a minor salivary gland biopsy showed chronic inflammatory infiltration with fibrosis, acinar atrophy and ductal ectasia. According to clinical and pathological findings a diagnosis of SS was made. Other cases of connective tissue diseases after IFN-beta treatment have been described. However, this is, to our knowledge, the first report on the development of primary SS after long time interval from MS onset in a woman treated with IFN-beta. Although there are no evidences about a possible role of IFN-beta in triggering SS yet, a screening for clinical and laboratory signs of SS should be assessed in MS patients during IFN-beta treatment.

摘要

相似文献

1
Long time interval between multiple sclerosis onset and occurrence of primary Sjögren's syndrome in a woman treated with interferon-beta.
Acta Neurol Scand. 2005 Sep;112(3):194-6. doi: 10.1111/j.1600-0404.2005.00455.x.
2
[Sjögren's syndrome and multiple sclerosis].[干燥综合征与多发性硬化症]
Neurologia. 2001 May;16(5):232-5.
3
Primary Sjogren's syndrome with central nervous system involvement.原发性干燥综合征伴中枢神经系统受累
Saudi Med J. 2009 Aug;30(8):1067-72.
4
A case of Sjögren's syndrome or multiple sclerosis? A diagnostic and therapeutic dilemma.干燥综合征还是多发性硬化症?诊断与治疗困境。
Rheumatol Int. 2002 Nov;22(6):256-8. doi: 10.1007/s00296-002-0240-9. Epub 2002 Sep 5.
5
Serum auto antibodies presence in multiple sclerosis patients treated with beta-interferon 1a and 1b.接受β-干扰素1a和1b治疗的多发性硬化症患者血清中自身抗体的存在情况。
J Neurovirol. 2000 May;6 Suppl 2:S57-61.
6
Effect of dose and frequency of interferon beta-1a administration on clinical and magnetic resonance imaging parameters in relapsing-remitting multiple sclerosis.干扰素β-1a给药剂量和频率对复发缓解型多发性硬化症临床及磁共振成像参数的影响
Funct Neurol. 2006 Jul-Sep;21(3):145-9.
7
[Development of binding antibodies to interferon-beta during treatment of multiple sclerosis with different types of interferon-beta].
Pol Merkur Lekarski. 2004 Jul;17(97):28-32.
8
Interferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy.干扰素β-1a主要通过减少灰质萎缩来减缓复发缓解型多发性硬化症患者脑萎缩的进展。
Mult Scler. 2007 May;13(4):490-501. doi: 10.1177/1352458506070446. Epub 2007 Feb 9.
9
Optic neuropathy as an initial manifestation of Sjögren's syndrome.视神经病变作为干燥综合征的首发表现
J Rheumatol. 1988;15(5):799-802.
10
[Gougerot-Sjögren syndrome. Central neurological involvement with recurrent development].[古热罗-舍格伦综合征。伴有反复进展的中枢神经系统受累]
Rev Neurol (Paris). 1993;149(10):554-6.

引用本文的文献

1
Patterns of autoantibody expression in multiple sclerosis identified through development of an autoantigen discovery technology.通过自身抗原发现技术的开发确定的多发性硬化症自身抗体表达模式。
J Clin Invest. 2025 Mar 3;135(5):e171948. doi: 10.1172/JCI171948.
2
Exploring Overlap Syndromes: An Atypical Case of Multiple Sclerosis With Anti-Sjogren's Syndrome Type B Antibody.探索重叠综合征:一例伴有抗干燥综合征B型抗体的多发性硬化症非典型病例。
J Med Cases. 2024 Dec;15(12):387-395. doi: 10.14740/jmc4336. Epub 2024 Oct 30.
3
Adverse side effects of Glatiramer acetate and Interferon beta-1a in patients with multiple sclerosis: A systematic review of case reports.
醋酸格拉替雷和干扰素β-1a治疗多发性硬化症患者的不良副作用:病例报告的系统评价
Curr J Neurol. 2023 Apr 4;22(2):115-136. doi: 10.18502/cjn.v22i2.13340.
4
Ocular adverse events from pharmacological treatment in patients with multiple sclerosis-A systematic review of the literature.多发性硬化症患者药物治疗的眼部不良反应——文献系统评价。
Syst Rev. 2021 Oct 28;10(1):280. doi: 10.1186/s13643-021-01782-7.
5
Safety, Tolerability, and Immunogenicity of Interferons.干扰素的安全性、耐受性和免疫原性。
Pharmaceuticals (Basel). 2010 Apr 20;3(4):1162-1186. doi: 10.3390/ph3041162.
6
Immunogenicity and other problems associated with the use of biopharmaceuticals.生物制药的免疫原性和其他问题。
Ther Adv Drug Saf. 2011 Jun;2(3):113-28. doi: 10.1177/2042098611406318.
7
Assessment of the effect of interferon-beta1a therapy on thyroid and salivary gland functions in patients with multiple sclerosis using quantitative salivary gland scintigraphy.利用定量唾液腺闪烁扫描评估干扰素β-1a疗法对多发性硬化症患者甲状腺和唾液腺功能的影响。
Mol Imaging Radionucl Ther. 2014 Jun;23(2):43-7. doi: 10.4274/mirt.53825. Epub 2014 Jun 5.
8
Interferons in Sjögren's Syndrome: Genes, Mechanisms, and Effects.干燥综合征中的干扰素:基因、机制及作用
Front Immunol. 2013 Sep 20;4:290. doi: 10.3389/fimmu.2013.00290.
9
Activation of innate immune responses through Toll-like receptor 3 causes a rapid loss of salivary gland function.通过Toll样受体3激活先天免疫反应会导致唾液腺功能迅速丧失。
J Oral Pathol Med. 2009 Jan;38(1):42-7. doi: 10.1111/j.1600-0714.2008.00700.x.